{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:19:37Z","timestamp":1761941977368,"version":"build-2065373602"},"reference-count":36,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,1,5]],"date-time":"2015-01-05T00:00:00Z","timestamp":1420416000000},"content-version":"vor","delay-in-days":765,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Bone Oncology"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1016\/j.jbo.2012.10.001","type":"journal-article","created":{"date-parts":[[2012,11,22]],"date-time":"2012-11-22T02:45:12Z","timestamp":1353552312000},"page":"74-80","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Skeletal morbidity rates over time in patients with bone metastases from solid tumors reported in bone modifying agents randomised trials"],"prefix":"10.1016","volume":"1","author":[{"given":"Michael","family":"Poon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marko","family":"Popovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Chow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry","family":"Lam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gillian","family":"Bedard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Urban","family":"Emmenegger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Simmons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Chow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.jbo.2012.10.001_bib1","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clinical Cancer Research"},{"issue":"6","key":"10.1016\/j.jbo.2012.10.001_bib2","doi-asserted-by":"crossref","first-page":"390","DOI":"10.3816\/CGC.2007.n.022","article-title":"Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases","volume":"5","author":"Saad","year":"2007","journal-title":"Clinical Genitourinary Cancer"},{"issue":"3","key":"10.1016\/j.jbo.2012.10.001_bib3","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1200\/JCO.1999.17.3.846","article-title":"Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 aredia breast cancer study group","volume":"17","author":"Theriault","year":"1999","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1016\/j.jbo.2012.10.001_bib4","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","article-title":"Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials","volume":"88","author":"Lipton","year":"2000","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.jbo.2012.10.001_bib5","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/bjc.1987.13","article-title":"The clinical course of bone metastases from breast cancer","volume":"55","author":"Coleman","year":"1987","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.jbo.2012.10.001_bib6","first-page":"27","article-title":"Bisphosphonates in oncology: evidence for the prevention of skeletal events in patients with bone metastases","volume":"3","author":"Polascik","year":"2009","journal-title":"Drug Design, Development and Therapy"},{"issue":"35","key":"10.1016\/j.jbo.2012.10.001_bib7","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"10","key":"10.1016\/j.jbo.2012.10.001_bib8","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1023\/A:1012506426440","article-title":"Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease","volume":"12","author":"Jagdev","year":"2001","journal-title":"Annals of Oncology"},{"issue":"16","key":"10.1016\/j.jbo.2012.10.001_bib9","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","article-title":"Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial\u2014the zoledronic acid lung cancer and other solid tumors study group","volume":"21","author":"Rosen","year":"2003","journal-title":"Journal of Clinical Oncology"},{"issue":"9768","key":"10.1016\/j.jbo.2012.10.001_bib10","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"issue":"5\u20136","key":"10.1016\/j.jbo.2012.10.001_bib11","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1159\/000082923","article-title":"The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer","volume":"67","author":"Delea","year":"2004","journal-title":"Oncology"},{"issue":"1","key":"10.1016\/j.jbo.2012.10.001_bib12","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.lungcan.2009.08.020","article-title":"Skeletal morbidity in lung cancer patients with bone metastases: demonstrating the need for early diagnosis and treatment with bisphosphonates","volume":"67","author":"Langer","year":"2010","journal-title":"Lung Cancer"},{"issue":"5","key":"10.1016\/j.jbo.2012.10.001_bib13","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1586\/era.10.47","article-title":"Management of metastatic spinal cord compression","volume":"10","author":"Shiue","year":"2010","journal-title":"Expert Review of Anticancer Therapy"},{"issue":"4","key":"10.1016\/j.jbo.2012.10.001_bib14","first-page":"302","article-title":"Mortality and complications following stabilization of femoral metastatic lesions: a population-based study of regional variation and outcome","volume":"52","author":"Ristevski","year":"2009","journal-title":"Canadian Journal of Surgery"},{"issue":"5","key":"10.1016\/j.jbo.2012.10.001_bib15","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/cncr.23259","article-title":"Effective inhibition of aromatase inhibitor\u2010associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole","volume":"112","author":"Bundred","year":"2008","journal-title":"Cancer"},{"issue":"9810","key":"10.1016\/j.jbo.2012.10.001_bib16","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","article-title":"Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial","volume":"379","author":"Smith","year":"2012","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jbo.2012.10.001_bib17","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00520-011-1120-1","article-title":"Comparing baseline symptom severity and demographics over two time periods in an outpatient palliative radiotherapy clinic","volume":"20","author":"Khan","year":"2012","journal-title":"Supportive Care in Cancer"},{"issue":"2","key":"10.1016\/j.jbo.2012.10.001_bib18","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0885-3924(01)00406-7","article-title":"Do hospital-based palliative teams improve care for patients or families at the end of life?","volume":"23","author":"Higginson","year":"2002","journal-title":"Journal of Pain and Symptom Management"},{"issue":"2","key":"10.1016\/j.jbo.2012.10.001_bib19","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/j.seminoncol.2004.11.015","article-title":"Integration of palliative medicine into comprehensive cancer care","volume":"32","author":"Lagman","year":"2005","journal-title":"Seminars in Oncology"},{"issue":"19","key":"10.1016\/j.jbo.2012.10.001_bib20","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"Journal of the National Cancer Institute"},{"issue":"1","key":"10.1016\/j.jbo.2012.10.001_bib21","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/cncr.11892","article-title":"Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.jbo.2012.10.001_bib22","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/annonc\/mdg367","article-title":"Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases","volume":"14","author":"Body","year":"2003","journal-title":"Annals of Oncology"},{"issue":"18","key":"10.1016\/j.jbo.2012.10.001_bib23","doi-asserted-by":"crossref","first-page":"6397S","DOI":"10.1158\/1078-0432.CCR-040030","article-title":"Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid","volume":"10","author":"Lipton","year":"2004","journal-title":"Clinical Cancer Research"},{"issue":"5","key":"10.1016\/j.jbo.2012.10.001_bib24","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/cncr.11571","article-title":"Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma","volume":"98","author":"Lipton","year":"2003","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.jbo.2012.10.001_bib25","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/cncr.20308","article-title":"Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.jbo.2012.10.001_bib26","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1093\/annonc\/mdh173","article-title":"Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial","volume":"15","author":"Tripathy","year":"2004","journal-title":"Annals of Oncology"},{"issue":"6","key":"10.1016\/j.jbo.2012.10.001_bib27","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1111\/j.1464-410X.2006.06279_7.x","article-title":"Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers","volume":"97","author":"Saad","year":"2006","journal-title":"British Journal of Urology International"},{"issue":"1","key":"10.1016\/j.jbo.2012.10.001_bib28","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3816\/CGC.2005.n.009","article-title":"Clinical benefit of zoledronic acid for the prevention of skeletal complications in advanced prostate cancer","volume":"4","author":"Saad","year":"2005","journal-title":"Clinical Prostate Cancer"},{"issue":"15","key":"10.1016\/j.jbo.2012.10.001_bib29","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1200\/JCO.2005.05.116","article-title":"Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial","volume":"23","author":"Kohno","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1016\/j.jbo.2012.10.001_bib30","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s10147-010-0074-5","article-title":"A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer","volume":"15","author":"Zaghloul","year":"2010","journal-title":"International Journal of Clinical Oncology"},{"issue":"17","key":"10.1016\/j.jbo.2012.10.001_bib31","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1093\/jnci\/djg038","article-title":"A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial)","volume":"95","author":"Dearnaley","year":"2003","journal-title":"Journal of the National Cancer Institute"},{"issue":"11","key":"10.1016\/j.jbo.2012.10.001_bib32","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"Journal of the National Cancer Institute"},{"issue":"5","key":"10.1016\/j.jbo.2012.10.001_bib33","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer Journal"},{"issue":"24","key":"10.1016\/j.jbo.2012.10.001_bib34","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1056\/NEJM199612123352401","article-title":"Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 aredia breast cancer study group","volume":"335","author":"Hortobagyi","year":"1996","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1016\/j.jbo.2012.10.001_bib35","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.urology.2010.05.026","article-title":"Zoledronic acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer","volume":"76","author":"Saad","year":"2010","journal-title":"Urology"},{"issue":"23","key":"10.1016\/j.jbo.2012.10.001_bib36","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1200\/JCO.2003.05.147","article-title":"Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer","volume":"21","author":"Small","year":"2003","journal-title":"Journal of Clinical Oncology"}],"container-title":["Journal of Bone Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137412000322?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137412000322?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:15:21Z","timestamp":1761941721000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212137412000322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S2212137412000322"],"URL":"https:\/\/doi.org\/10.1016\/j.jbo.2012.10.001","relation":{},"ISSN":["2212-1374"],"issn-type":[{"type":"print","value":"2212-1374"}],"subject":[],"published":{"date-parts":[[2012,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Skeletal morbidity rates over time in patients with bone metastases from solid tumors reported in bone modifying agents randomised trials","name":"articletitle","label":"Article Title"},{"value":"Journal of Bone Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbo.2012.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier GmbH.","name":"copyright","label":"Copyright"}]}}